[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Can Krystal Biotech's Gene Therapy Pipeline Finally Justify the Premium Beyond VYJUVEK?

Krystal Biotech Inc (KRYS) reports second-quarter 2026 earnings before market open on August 3, with analysts expecting continued profitability as the company scales its commercial operations. The central question is whether KRYS can sustain its recent momentum of beating estimates while navigating the transition from a clinical-stage biotech to a commercial powerhouse. With the stock trading at $341.12 and Wall Street maintaining overwhelmingly bullish sentiment, this report will test whether the company's growth trajectory justifies its premium valuation.

Krystal Biotech is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines for rare diseases, with its lead product VYJUVEK approved for dystrophic...

Fundamentals

See More
  • Market Capitalization, $K 10,056,214
  • Shares Outstanding, K 29,480
  • Annual Sales, $ 389,130 K
  • Annual Income, $ 204,830 K
  • EBIT $ 179 M
  • EBITDA $ 185 M
  • 60-Month Beta 0.50
  • Price/Sales 27.79
  • Price/Cash Flow 50.33
  • Price/Book 8.47

Options Overview Details

View History
  • Implied Volatility 45.27% (-12.89%)
  • Historical Volatility 55.08%
  • IV Percentile 50%
  • IV Rank 43.68%
  • IV High 59.65% on 10/31/25
  • IV Low 34.12% on 05/13/26
  • Expected Move (DTE 18) 21.25 (6.88%)
  • Put/Call Vol Ratio 4.10
  • Today's Volume 954
  • Volume Avg (30-Day) 353
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 7,374
  • Open Int (30-Day) 6,131
  • Expected Range 287.48 to 329.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.70
  • Number of Estimates 3
  • High Estimate $1.90
  • Low Estimate $1.59
  • Prior Year $1.29
  • Growth Rate Est. (year over year) +31.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
303.04 +0.87%
on 08/03/26
382.13 -20.00%
on 07/09/26
-69.38 (-18.50%)
since 07/02/26
3-Month
251.97 +21.32%
on 05/04/26
382.54 -20.09%
on 06/30/26
+39.65 (+14.90%)
since 05/01/26
52-Week
130.50 +134.24%
on 08/04/25
382.54 -20.09%
on 06/30/26
+148.71 (+94.73%)
since 08/01/25

Most Recent Stories

More News
Stocks Rally on Easing Geopolitical Risks and US Economic Strength

The S&P 500 Index ($SPX ) (SPY ) today is up +1.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.081%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.40%. September E-mini S&P futures...

ALK : 49.56 (+4.45%)
GOOGL : 375.15 (+5.34%)
UAL : 127.80 (+5.33%)
ATKR : 93.51 (+28.17%)
DDOG : 273.82 (+2.18%)
SUPN : 48.00 (+7.55%)
CRCL : 60.17 (-3.90%)
$IUXX : 28,684.47 (+1.45%)
FICO : 1,043.78 (-7.05%)
ZNU26 : 108-120 (+0.35%)
MSFT : 487.40 (+4.88%)
TSLA : 322.16 (+3.52%)
Stocks Supported by Easing Middle East Tensions

The S&P 500 Index ($SPX ) (SPY ) today is up +0.84%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.47%. September E-mini S&P futures...

ALK : 49.56 (+4.45%)
ADI : 361.42 (-1.63%)
CRCL : 60.17 (-3.90%)
SLB : 49.33 (-0.52%)
OXY : 55.62 (-2.54%)
FANG : 198.39 (-2.25%)
FERG : 252.90 (+7.92%)
STX : 823.71 (-3.79%)
WDC : 522.58 (-4.09%)
AMD : 481.59 (+1.14%)
SPY : 756.33 (+1.24%)
GME : 18.77 (-13.58%)
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance...

KRYS : 300.02 (-12.05%)
Can Krystal Biotech's Gene Therapy Pipeline Finally Justify the Premium Beyond VYJUVEK?

Barchart Research What to Expect from KRYS Earnings KRYS Generated July 31, 2026 Current Price $341.12 EPS Estimate $$1.70 Consensus Rating Strong Buy Average Move 7.71% Can Krystal Biotech's Gene Therapy...

KRYS : 300.02 (-12.05%)
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August...

KRYS : 300.02 (-12.05%)
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

NEW YORK , July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: 

KRYS : 300.02 (-12.05%)
TMHC : 72.45 (-0.03%)
AVNS : 24.99 (+0.04%)
BRK.A : 768,880.56 (+0.30%)
TPC : 86.31 (+3.06%)
BRK.B : 512.20 (+0.13%)
SPGI : 410.76 (-0.28%)
VVX : 91.65 (+1.56%)
3 Biotech Firms With Major Potential Catalysts in the Coming Months

The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.

KRYS : 300.02 (-12.05%)
VERA : 31.80 (-0.93%)
ADMA : 8.65 (+2.25%)
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan  VYJUVEK is the first genetic...

KRYS : 300.02 (-12.05%)
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference...

KRYS : 300.02 (-12.05%)
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK)...

KRYS : 300.02 (-12.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 385.51
2nd Resistance Point 376.41
1st Resistance Point 358.76
Last Price 300.02
1st Support Level 332.01
2nd Support Level 322.91
3rd Support Level 305.26

See More

52-Week High 382.54
Last Price 300.02
Fibonacci 61.8% 286.26
Fibonacci 50% 256.52
Fibonacci 38.2% 226.78
52-Week Low 130.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.